Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

Hope S. Rugo(City of Hope), Sara M. Tolaney(Harvard University)

npj Breast Cancer

November 5, 2022

10.1038/s41523-022-00482-2

Cited by 81

Related Papers

Palbociclib and Letrozole in Advanced Breast Cancer

|New England Journal of Medicine|2016|2.9k

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

|New England Journal of Medicine|2022|2.5k

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

|Annals of Oncology|2016|2.1k

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

|The Lancet|2020|1.8k

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

|Annals of Oncology|2021|1.4k